OrthoPediatrics (KIDS) Guidance summary

Opening remarks and agenda

• The call opened with introductions and a reminder of forward-looking statements and non-GAAP measures, emphasizing risks and the use of supplemental financial metrics.

Preliminary third quarter 2025 results

• Helped over 37,100 children in Q3 2025, totaling approximately 1.3 million since inception.

• Preliminary Q3 2025 net revenue was $61.2 million, up 12% year-over-year.

• Domestic Q3 net revenue grew 14% to $48.7 million; international revenue rose 6% to $12.5 million.

• Excluding 7D capital sales, Q3 net revenue was $60.7 million, up 17% year-over-year.

Guidance on key objectives and revised 2025 financial guidance

• Full-year 2025 revenue now expected at $233.5–$234.5 million, down from prior $237.0–$242.0 million guidance, reflecting 14–15% year-over-year growth.

• Long-term annual revenue growth is now guided at 12% or greater for the next several years, with a focus on predictability.

• Free cash flow break-even is targeted for 2026, with the first quarter of free cash flow positivity expected in Q4 2025.

• Gross margin guidance remains at 72%-73% for 2025, with Adjusted EBITDA expected between $15M and $17M.

• Annual set deployment guidance remains at $15.0 million.